919347-18-5

Basic information

• Product Name: N,N-diMethyl-1-(5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanaMine
• Synonyms: N,N-diMethyl-1-(5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanaMine;3-PYRIDINEMETHANAMINE, N,N-DIMETHYL-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-;N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-Pyridinemethanamine
• CAS NO: 919347-18-5
• Molecular Formula: C14H23BN2O2
• Molecular Weight: 262.15562
• Mol File: 919347-18-5.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-diMethyl-1-(5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanaMine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-diMethyl-1-(5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanaMine(919347-18-5)
• EPA Substance Registry System: N,N-diMethyl-1-(5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanaMine(919347-18-5)

Safety Data

• Hazardous Substances Data: 919347-18-5(Hazardous Substances Data)

Upstream product

• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 
• 73183-34-3 bis(pinacol)diborane 

Relevant articles and documents

3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF

4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Pyrrolopyrimidines and Pyrrolopyridines

Compounds of formula I in free or salt or solvate form, wherein X, T1, T3 and T4 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.